glp-1 stall ✨ Have you hit a weight loss on therapy? ✨ At Dupre Medical Clinic, we understand how frustrating it can be when the scale stops moving—even with consistent effort and S4.E8: My Life on GLP-1:

Whether to switch is a clinical decision for you and your prescriber

This does not affect our editorial rankings

Why the Dual Mechanism Works Better: GIP activation enhances insulin secretion and may increase energy expenditure, amplifying semaglutide's effects Synergistic appetite suppression through dual pathway activation Improved glycemic control even in non-diabetic populations Advantages of Tirzepatide: Highest weight loss efficacy: 20-25% average reduction Superior cardiometabolic improvements Newer mechanism: ongoing research may unlock additional benefits Considerations: Shorter clinical history than semaglutide (approved for weight loss in 2023) Slightly higher GI side effect incidence in early trials Higher cost, available with transparent cash-pay pricing at Hartwater Wellness Which GLP-1 Medication Is Right for You

The medication does not cure obesity

10.1038/nrneph.2017.123 [DOI] [PubMed] [Google Scholar] 85

Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose